Phaseline

Companies › Shanghai Ark Biopharmaceutical

Shanghai Ark Biopharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Other, Infectious disease; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ziresovir (AK0529)
Fusion glycoprotein F0 inhibitor
–Phase 3Respiratory Synctial Virus Infections; Respiratory Syncytial Virus InfectionsDec 2028
AK0406–Phase 1Healthy ParticipantsApr 2027
AK0610–Phase 1Healthy Volunteer Study–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06775405Ziresovir (AK0529)Phase 3Respiratory Synctial Virus InfectionsInfectious diseaseApr 2025
NCT06996704AK0610Phase 1Healthy Volunteer StudyOtherMay 2025
NCT07432698AK0406Phase 1Healthy ParticipantsOtherApr 2027
NCT07658534Ziresovir (AK0529)Phase 2Respiratory Syncytial Virus InfectionsInfectious diseaseDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Atea Pharmaceuticals Basilea Pharmaceutica Tortugas Neuroscience BioAegis Therapeutics Ensysce Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.